Fennec Pharmaceuticals (FENC) vs ProKidney (PROK)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Fennec Pharmaceuticals (FENC) has outperformed ProKidney (PROK) over the past year, gaining 66.1% versus a loss of 52.5%. Over five years, FENC leads with a +35.8% price change compared with -89.5% for PROK. Fennec Pharmaceuticals is the larger company by market cap ($462.1 million vs $415.2 million), about 1.1 times the size, while ProKidney is growing revenue faster (+1075.0% vs -6.1%).
Fennec Pharmaceuticals converts more of its revenue into profit, with a net margin of -21.8% versus -7725.2%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | FENC | PROK |
|---|---|---|
| Share price | $13.09 | $1.04 |
| Market cap | $462.14M | $415.21M |
| 1-day change | -2.68% | -1.89% |
| YTD return | +70.00% | -53.57% |
| 1-year return | +66.12% | -52.51% |
| 5-year return | +35.79% | -89.49% |
| P/E ratio (TTM) | 436.33 | — |
| Forward P/E | 12.47 | — |
| EPS (TTM) | $0.03 | $-0.61 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $44.64M | $893.00K |
| Revenue growth (YoY) | -6.09% | +1075.00% |
| Net income (latest FY) | $-9.74M | $-68.99M |
| Operating margin | -14.07% | -18477.83% |
| Net margin | -21.82% | -7725.20% |
| 52-week high | $13.85 | $2.65 |
| 52-week low | $5.65 | $0.87 |
| Distance from 52-week high | -5.49% | -60.75% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +34.45% | +525.00% |
| Average volume | 220.87K | 1.44M |
| Shares outstanding | 35.31M | 209.63M |
| Employees | 35 | 231 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- FENC has outperformed PROK by 118.6 percentage points over the past year.
- Fennec Pharmaceuticals is more profitable, keeping -21.8 cents of every revenue dollar as net income versus -7725.2 cents for ProKidney.
- ProKidney grew revenue faster in its latest fiscal year (+1075.00% vs -6.09%).
About Fennec Pharmaceuticals
FENC stock →Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 35 employees
About ProKidney
PROK stock →ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 231 employees
FENC vs PROK FAQ
Which is bigger, Fennec Pharmaceuticals or ProKidney?
Fennec Pharmaceuticals (FENC) is larger, with a market capitalization of $462.14M compared with $415.21M for ProKidney (PROK).
Which stock has performed better over the past year, FENC or PROK?
FENC returned +66.12% over the past 12 months, compared with -52.51% for PROK (price return, excluding dividends). Past performance does not predict future results.
Are Fennec Pharmaceuticals and ProKidney in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.